bioAffinity Technologies prices $4.8m public offering at $2.50 per share

bioAffinity Technologies Inc. (NASDAQ: BIAF) priced a public offering of 1,921,799 shares at $2.50 per share, generating gross proceeds of $4.8 million before fees and expenses, according to a press release statement.

The biotechnology company, which focuses on noninvasive tests for early-stage cancer detection, also offered pre-funded warrants at $2.493 each as an alternative to common stock. Each pre-funded warrant is exercisable for one share of common stock with an exercise price of $0.007 per share.

WallachBeth Capital LLC served as the sole placement agent for the offering. The transaction is expected to close on or about September 30, 2025, subject to customary closing conditions.

The securities are being offered under a registration statement on Form S-1 that was previously filed and declared effective by the Securities and Exchange Commission. The company will file a final prospectus with the SEC relating to the offering.

bioAffinity Technologies trades on NASDAQ under the symbols BIAF and BIAFW. WallachBeth Capital provides capital markets and investment banking services to healthcare companies, including initial public offerings, follow-on issues, and private transactions.

You May Also Be Interested In